Bringing Personalized Therapeutic Cancer Vaccines to the world, one patient at a time.
The company uses its proprietary GT-EPIC™ platform to provide every cancer patient with a custom vaccine therapeutic designed to include up to 40 of their unique tumor’s neoantigens (abnormal mutations produced by cancer cells). In most cases this means that the vaccine will include all of the patient’s targetable neoantigens.
PTCVs are administered intra-dermally into skin tissue in a patient’s arms together with a cytokine adjuvant and electroporation. There, far away from the tumor microenvironment, they direct the immune system to create tumor infiltrating lymphocytes (TILs) programmed according to the identity of the delivered neoantigens. The majority of these TIL populations are new and expanded CD8 T-effector memory cells with cytotoxic phenotype, a type of T cell known to have the ability to kill tumor cells.
These TILs then travel to tumor tissues, wherever they may be in the patient’s body, and harness the power of the patient’s own immune system to coordinate an effort aimed at reducing, or even eradicating, the cancer. Because all tumors express tumor neoantigens the mechanisms of action of PTCVs may apply to the treatment of all cancers. The majority of Geneos clinical development to date has been done in hepatocellular carcinoma with planning now underway for a potentially registrational clinical trial.
All Play Roles to Maximize Effectiveness
- Industry-leading neoantigen carrying capacity in a space where the more neoantigens the better
- Designed to drive tumor targeted, neoantigen-specific, immune response
- Drives Th1 response to vaccine encoded antigens
- Adjuvant remains localized to skin; no systemic levels achieved
- Enhances cellular uptake of DNA plasmid at injection site1
Latest News
Upcoming Conferences
Please stay tuned for a list of upcoming conferences Geneos will be attending.
Geneos will be attending the following upcoming conferences:
- Fierce Biotech Summit
October 1, 2024 - Stuart and Molly Sloan Precision Oncology Institute Cancer Vaccine Symposium
October 1, 2024 - BIO Investor Forum
October 15-16, 2024 - World Vaccine Congress Europe
October 29-31, 2024 - SU2C Innovation Summit on Cancer Detection and Vaccines
November 4, 2024 - Personalized Cancer Vaccine Summit
December 3-5, 2024
- CELLECTRA® is a registered trademark of Inovio Pharmaceuticals; EP Device & pIL12 exclusively licensed for Geneos use